Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (11c)abt-627
2. 2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic Acid
3. A 127722
4. A 127722.5
5. A 147627
6. A-127722
7. A-127722.5
8. A-147627
9. A127722
10. A127722.5
11. A147627
12. Abt 627
13. Abt-627
14. Abt627
15. Atrasentan
16. Xinlay
1. 195733-43-8
2. Atrasentan Hcl
3. Atrasentan (hydrochloride)
4. Atrasentan Hydrochloride [usan]
5. Abbot-147627
6. E4g31x93za
7. 3-pyrrolidinecarboxylicacid,4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-,hydrochloride (1:1), (2r,3r,4s)-
8. 195733-43-8 (hcl)
9. A-147627.1
10. Atrasentan Hydrochloride (usan)
11. Abbott 147627
12. Unii-e4g31x93za
13. (2r,3r,4s)-1-((dibutylcarbamoyl)methyl)-2-(p-methoxyphenyl)-4-(3,4-(methylenedioxy)phenyl)-3-pyrrolidinecarboxylic Acid, Monohydrochloride
14. (2r,3r,4s)-4-(benzo[d][1,3]dioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic Acid Hydrochloride
15. (2r,3r,4s)-4-(benzo[d][1,3]dioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic Acid Hydrochloride.
16. A 147627.1
17. D03009
18. (2r,3r,4s)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic Acid Hydrochloride
19. Chembl2106068
20. Dtxsid20173240
21. Ex-a4175
22. Atrasentan Hydrochloride [mi]
23. Hy-15403a
24. Mfcd13194884
25. Cs-1373
26. Atrasentan Hydrochloride [mart.]
27. Atrasentan Hydrochloride [who-dd]
28. Bs-16407
29. Atrasentan Hydrochloride, >=98% (hplc)
30. D82853
31. 733a438
32. A930316
33. Abt-627;abt627;abt 627;abbott 147627
34. Q27276859
35. (2r,3r,4s)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(n,n-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic Acid Hydrochloride Salt
36. (2r,3r,4s)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic Acid;hydrochloride
37. (2r,3r,4s)-4-(benzo[d][1,3]dioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylicacidhydrochloride
38. 3-pyrrolidinecarboxylic Acid, 4-(1,3-benzodioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, Monohydrochloride, (2r,3r,4s)-
39. 3-pyrrolidinecarboxylic Acid, 4-(1,3-benzodioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, Monohydrochloride, (2r-(2.alpha.,3.beta.,4.alpha.))
40. 3-pyrrolidinecarboxylic Acid, 4-(1,3-benzodioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, Monohydrochloride, (2r-(2alpha,3beta,4alpha))
Molecular Weight | 547.1 g/mol |
---|---|
Molecular Formula | C29H39ClN2O6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 12 |
Exact Mass | 546.2496647 g/mol |
Monoisotopic Mass | 546.2496647 g/mol |
Topological Polar Surface Area | 88.5 Ų |
Heavy Atom Count | 38 |
Formal Charge | 0 |
Complexity | 734 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Treatment of nephropathy
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Endothelin A Receptor Antagonists
Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN A RECECPTORS. (See all compounds classified as Endothelin A Receptor Antagonists.)
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?